NCT07203469 Where Wild Things Grow: Nature- and Activity-based Group Interventions for Neurodivergent Children and Youth
| NCT ID | NCT07203469 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sorlandet Hospital HF |
| Condition | Neurodevelopmental Outcomes |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-09-01 |
| Primary Completion | 2026-06-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2025-09-01 with a primary completion date of 2026-06-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this action research project is to develop and implement nature- and activity-based group interventions across health care, school and leisure settings in Southern Norway. The interventions are tailored to support the mental health, self-efficacy and daily life functioning of children and youth in the Agder region, with a particular focus on youngsters who struggle due to neurodivergence, such as Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) or Tourette's syndrome. The main questions we aim to answer are: 1. To what extent does nature- and activity-based outdoor education contribute to improvements in children's quality of life? 2. To what extent does nature- and activity-based interventions in a health care setting improve children's self-efficacy, self-esteem and quality of life? 3. Is there a difference in physiological reactions between nature-based provision of education or therapy and traditional indoor provision of education or therapy? Participants will take part in a 12-week school-based or health care intervention.
Eligibility Criteria
Inclusion Criteria: * In PhD 1, participants are recruited on class-level (all) or individual (identified need). * In PhD 2, inclusion criteria are patients that participate in the specific interventions. Exclusion Criteria: * In PhD 2, exclusion criteria include substance misuse, acute psychosis, current suicidal behavior/ideation, and severe eating disorders.
Contact & Investigator
Carina R Fernee, PhD
PRINCIPAL INVESTIGATOR
Sørlandet Hospital HF
Frequently Asked Questions
Who can join the NCT07203469 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 18 Years, studying Neurodevelopmental Outcomes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07203469 currently recruiting?
Yes, NCT07203469 is actively recruiting participants. Contact the research team at carina.fernee@sshf.no for enrollment information.
Where is the NCT07203469 trial being conducted?
This trial is being conducted at Kristiansand, Norway, Kristiansand, Norway.
Who is sponsoring the NCT07203469 clinical trial?
NCT07203469 is sponsored by Sorlandet Hospital HF. The principal investigator is Carina R Fernee, PhD at Sørlandet Hospital HF. The trial plans to enroll 240 participants.